{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-027111","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.863698+00:00","generated_at":"2026-06-05T02:54:53.292464+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PepGen reports FY2023 net loss $78.6M; cash runway into 2026 after $80M offering","bullets":["Enrollment complete for PGN-EDO51 5 mg/kg cohort; preliminary data expected mid-2024.","CONNECT2-EDO51 Phase 2 trial for DMD initiated in UK; designed to support accelerated approval.","FREEDOM-DM1 Phase 1 trial enrolling; preliminary data from 5 mg/kg cohort expected H2 2024.","Cash $110.4M as of Dec 31, 2023; combined with $80M Feb 2024 offering extends runway into 2026.","Net loss $78.6M for FY2023 vs $69.1M in FY2022; R&D expenses $68.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-027111","json":"https://secwatch.observer/filing/0000950170-24-027111.json","markdown":"https://secwatch.observer/filing/0000950170-24-027111.md","text":"https://secwatch.observer/filing/0000950170-24-027111.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024027111/0000950170-24-027111-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024027111/pepg-20240306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T02:54:53.292464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a348f642eb90b5331ff19c25eefde756c9a5ce86","claim":"PepGen Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On March 6, 2024, PepGen Inc. announced its financial results for the year ended December 31, 2023 and other business updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024027111/0000950170-24-027111-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}